ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1748

Interstitial Lung Disease in ANCA-Positive Vasculitis Patients

Andy Abril1, Minkyung Kwon,2, Isabel Mira-Avendano3, Carlos Rojas4 and Andras Khoor5, 1Rheumatology, Mayo Clinic Florida, Jacksonville, FL, 2Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL, 3Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL, 4Radiology, Mayo Clinic, Jacksonville, FL, 5Pathology, Mayo Clinic, Jacksonville, FL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANCA, interstitial lung disease and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis – ANCA-Associated Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rarely, ANCA-positive vasculitis patients are found to have interstitial lung disease (ILD). Clinical characteristics and prognosis are not well known in these patients. The largest report to date is from Japan, describing microscopic polyangitis (MPA) as the most common type of ANCA vasculitis associated to ILD.

Methods:

We retrospectively reviewed 26 patients at Mayo Clinic Florida for the past 10 years diagnosed with both ANCA-positive vasculitis and ILD (AAV-ILD). We compared the clinical characteristics of AAV-ILD to idiopathic pulmonary fibrosis (IPF) and idiopathic pneumonia with autoimmune features (IPAF) patients

Results:

There were 24 AAV patients. 11 were male and 13 were female. 14 patients had microscopic polyangitis (MPA), 8 patients had granulomatosis polyangitis (GPA), and 2 patients had eosinophilic granulomatosis polyangitis (EGPA). Usual interstitial pneumonia (UIP) pattern was found in 11 patients and other patterns were inconsistent with UIP.

P-ANCA and anti-MPO were positive in most MPA patients and c-ANCA and anti-proteinase-3 were positive in most GPA patients. Cyclophosphamide and corticosteroids were the mainstay of therapy, and rituximab was used in 13 patients. A total of 5 patients died. Death was directly related to the progression of ILD in 4 patients.

Conclusion:

We were able to identify the characteristics of ILD in ANCA-positive vasculitis patients. We observed that a fair number of PR3-positive/GPA patients do have ILD, comparable to MPA. This is to our knowledge the largest case series of clinically confirmed ANCA vasculitis with ILD reported in North America.

Table 1.  Comparison  between AAV-ILD, Idiopathic pulmonary fibrosis (IPF), and idiopathic pneumonia with autoimmune features (IPAF)

 

Characteristic

AAV-ILD

(N=24)

IPF

(N=29)

IPAF

(N=22)

P value

Male gender

11 (45.8%)

17 (58.6%)

9 (40.9%)

0.42

Age, years

73 (19, 94) a

71 (55, 86) a

67 (35-84) b

0.016

Smoking history, pack-years

13 (0, 75)

10 (0, 70)

0 (0, 60)

0.22

Pulmonary hypertension

12/22 (54.5%) ab

16/20 (80.0%) a

2/8 (25.0%) b

0.025

Autoantibodies

 

 

 

 

     ANA

10/22 (45.5%)

7/19 (36.8%)

10 (45.5%)

0.82

     RF

12/19 (63.2%) a

5/15 (33.3%) ab

3 (13.6%) b

0.004

     Anti CCP

0/15 (0.0%)

0/7 (0.0%)

0 (0.0%)

1.00

     SS-A

3/17 (17.6%)

0/11 (0.0%)

7 (31.8%)

0.089

     SS-B

1/17 (5.9%)

0/11 (0.0%)

1 (4.5%)

1.00

     RNP

0/17 (0.0%) a

0/11 (0.0%) a

5 (22.7%) a

0.045

     Anti Smith

0/17 (0.0%)

0/11 (0.0%)

0 (0.0%)

1.00

     Jo-1

0/17 (0.0%)

0/11 (0.0%)

2 (9.1%)

0.50

     SCL-70

1/17 (5.9%)

0/12 (0.0%)

1 (4.5%)

1.00

     Centromere

0/12 (0.0%)

0/1 (0.0%)

0/19 (0.0%)

1.00

     Myositis specific antibodies

0/1 (0.0%)

N=0

19/21 (90.5%)

0.14

     ds-DNA

1/15 (6.7%)

0/1 (0.0%)

1/7 (14.3%)

1.00

     serum IgG4

1/3 (33.3%)

0/1 (0.0%)

0/1 (0.0%)

1.00

     anti-GBM antibody

1/1 (100%)

0/1 (0.0%)

0/1 (0.0%)

1.00

Pulmonary function tests at initial visit

 

 

 

 

     Forced vital capacity, L/sec

2.7 (1.5, 4.8), n=23

2.5 (0.9, 3.5), n=28

2.2 (1.1, 3.7), n=22

0.25

     Forced vital capacity, % of predicted

76 (41, 106), n=23 a

71 (41, 102), n=28 b

63 (45, 124), n=22 b

0.049

     DLCO, ml CO(STPD)/min/mmHg

13.7 (5.0, 19.5), n=21

9.3 (6.0, 19.8), n=25

12.4 (2.2, 22.7), n=20

0.062

     DLCO, % of predicted

55 (20, 87), n=21 a

41 (26, 77), n=25 b

49 (12, 79), n=20 ab

0.019

Follow-up after initial evaluation, years

3.5 (0.0, 12.0)

2.2 (0.0, 10.0)

0.9 (0.1, 3.6)

–

AAV-ILD, ANCA-associated vasculitis with interstitial lung disease; DLCO, diffusing capacity; Data are given as median (minimum, maximum) for numeric variables and number (percent) for categorical variables.  P values result from the nonparametric Kruskal-Wallis test for numeric variables and the Fisher exact test for categorical variables.  Pairwise comparisons were performed when the P value was less than 0.05; superscripts a and b are given to indicate pairwise differences (P<0.05) where groups without a common superscript were considered to have a statistically significant difference.


Disclosure: A. Abril, None; M. Kwon,, None; I. Mira-Avendano, None; C. Rojas, None; A. Khoor, None.

To cite this abstract in AMA style:

Abril A, Kwon, M, Mira-Avendano I, Rojas C, Khoor A. Interstitial Lung Disease in ANCA-Positive Vasculitis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/interstitial-lung-disease-in-anca-positive-vasculitis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-lung-disease-in-anca-positive-vasculitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology